<?xml version="1.0" encoding="UTF-8"?>
<ref id="B106-biomedicines-08-00109">
 <label>106.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Hoffmann</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Kleine-Weber</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Schroeder</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Kr√ºger</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Herrler</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Erichsen</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Schiergens</surname>
    <given-names>T.S.</given-names>
   </name>
   <name>
    <surname>Herrler</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Wu</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Nitsche</surname>
    <given-names>A.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</article-title>
  <source>Cell</source>
  <year>2020</year>
  <pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id>
  <?supplied-pmid 32142651?>
  <pub-id pub-id-type="pmid">32142651</pub-id>
 </element-citation>
</ref>
